The Effect of Pharmacogenomic Testing on Response and Remission Rates in the Acute Treatment of Major Depressive Disorder: A Meta-Analysis

Major depressive disorder (MDD) is a highly prevalent and disabling mental illness affecting more than 350 million people globally as the leading cause of disability worldwide (WHO, 2017). Depression treatment guidelines recommend the use of evidence-based antidepressants in the acute treatment of moderate to severe depression (Kennedy et al., 2016; McIntyre, 2015). Evidence-based treatments are identified through randomized controlled trials (RCTs) assessing the clinical efficacy, safety and tolerability of new treatments.

Source: Journal of Affective Disorders - August 13, 2018 Category: Neurology Authors: Joshua D. Rosenblat, Yena Lee, Roger S. McIntyre Tags: Review article Source Type: research